| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/14/2005 | WO2003051287A3 Topical compositions and methods for treatment of adverse effects of ionizing radiation |
| 04/14/2005 | WO2003027228A3 Receptors and membrane-associated proteins |
| 04/14/2005 | WO2003015712A3 Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin |
| 04/14/2005 | WO2002079417A3 Methods of delivery of exogenous proteins to the cytosol and uses thereof |
| 04/14/2005 | US20050080250 Methods of stimulating growth of stromal cells in a human |
| 04/14/2005 | US20050080249 Genetic engineering; isolation polypeptides; heterogeneity amino acid sequences |
| 04/14/2005 | US20050080237 Oligomeric molecules and uses thereof |
| 04/14/2005 | US20050080236 Virus suppressing factor (VSF) for use in treatment and prevention of viral infection in animal and humans |
| 04/14/2005 | US20050080235 Ret ligand (RetL) for stimulating neural and renal growth |
| 04/14/2005 | US20050080234 Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor |
| 04/14/2005 | US20050080233 Expression vector comprising nucleotide sequences coding bacterial outer membrane protein for use in diagnosis, prevention and treatment of microorganismal infection |
| 04/14/2005 | US20050080231 Small peptides having apoptotic activities and their applications |
| 04/14/2005 | US20050080140 Administering peroxisome proliferator-activated receptor (PPAR) delta agonist; a prostacyclin synthase gene or a protein encoded by the gene; rheumatoid arthritis, osteoarthritis, Crohn's disease, Guillain-Barre syndrome, skin disorders, post by-pass surgery restenosis, transplantation rejection |
| 04/14/2005 | US20050080133 Methods of inhibiting osteoclast activity |
| 04/14/2005 | US20050080122 Anti-viral compounds |
| 04/14/2005 | US20050080041 Method and composition for the treatment of adenoviral ocular infections |
| 04/14/2005 | US20050080034 Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies |
| 04/14/2005 | US20050080031 Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV |
| 04/14/2005 | US20050080030 Amplifying efficiency of transfection, providing aggregation, exposing to vector, monitoring efficiency of transfection |
| 04/14/2005 | US20050080026 Nucleic acid molecule of MAP kinase interacting kinase gene family or polypeptide encoded thereby or fragment or variant of nucleic acid molecule, polypeptide or antibody, aptamer or receptor recognizing a nucleic acid molecule of gene family or polypeptide encoded thereby; treating metabolic diseases |
| 04/14/2005 | US20050080017 Viricide against hepatitis virus; pyrrole derivatives as, for example, 3-acetyl-4,5-dimethyl-2-pyrrole carboxylic acid |
| 04/14/2005 | US20050080016 Tripeptides and tripeptide derivatives for the treatment of postlesional diseases of the nervous system |
| 04/14/2005 | US20050080015 Carboline-3-carboxylic acid modified related sequences of Ala-Arg-Pro-Ala-Lys, their synthesis and use as thromobolytic agent |
| 04/14/2005 | US20050080014 Thrombopoietic compounds |
| 04/14/2005 | US20050080013 a 15 to 22-residue polypeptide analog that forms an amphipathic alpha helix in the presence of lipids; multimeric Apo-A-1agonist; anticholesterol agents; hypercholesterolemia, septic shock |
| 04/14/2005 | US20050080011 Stabilization of pharmaceutical protein formulations with small peptides |
| 04/14/2005 | US20050080010 Suppression of immune response via inhibition of cathepsin S |
| 04/14/2005 | US20050080009 Storage-stable, liquid fibrinogen formulation |
| 04/14/2005 | US20050080008 Administering bactericidal permeability increasing protein products; anticoagulants; without severe adverse side effects |
| 04/14/2005 | US20050080007 Use in the control of glycemia in aging patients, GH deficient patients, diabetic patients and obese patients |
| 04/14/2005 | US20050080006 Apo2L/TRAIL formulations including lyophilized and crystal compositions; may be used in inducing apoptosis in mammalian cells including cancer cells by exposing mammalian cells to an effective amount of an Apo-2 ligand formulation described herein |
| 04/14/2005 | US20050080005 Macrocyclic peptides active against the hepatitis C virus |
| 04/14/2005 | US20050080004 Including teicoplanin which shares many chemical and microbiological characteristics with vancomycin, but which possesses higher activity against many Gram-positive bacteria and is less nephrotoxic |
| 04/14/2005 | US20050080002 Methods for the treatment and prevention of cancer |
| 04/14/2005 | US20050079998 Anti-lipemic drug cromprising effector of sterol regulatory element binding protein-1 (SREBP-1) and serum cholesterol inhibitor, sphingolipid |
| 04/14/2005 | US20050079996 Remedies for liver diseases, hyperlipemia and diabetes |
| 04/14/2005 | US20050079612 Use of obg3 for promoting central nervous system remyelination |
| 04/14/2005 | US20050079610 Using short interfering RNA's specific to oncogene (fos) as tool in prevention and treatment of infection, allergies, cell proliferatiove, inflammatory and autoimmune diseases |
| 04/14/2005 | US20050079597 Antimicrobial composition |
| 04/14/2005 | US20050079585 Complement depletion using recombinant human C3-derivatives |
| 04/14/2005 | US20050079584 Modified factor VIII |
| 04/14/2005 | US20050079581 Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor |
| 04/14/2005 | US20050079577 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/14/2005 | US20050079576 Binding polypeptide, for use in the detection and treatment of prostate cancer |
| 04/14/2005 | US20050079575 Human receptor molecules |
| 04/14/2005 | US20050079572 Expression vector comprising nuclelotide sequences coding brain acid soluble protein 1 (BASP1) for use in prevention and treatment of infection, cell proliferative, inflammatory and autoimmune disorders; gene therapy; immunotherapeutics |
| 04/14/2005 | US20050079553 SSX-2 peptides presented by HLA class II molecules |
| 04/14/2005 | US20050079550 Isolated protein molecule, flh2882, a GPCR showing homology to the 5HT family of receptors |
| 04/14/2005 | US20050079543 direct interaction with the ligand-bound receptor and activation of one or more transcription factors; unaffected by the presence or concentration of second messengers; direct interaction with tyrosine kinase domains; absence of interaction with G-proteins; transcriptional stimulation of target genes |
| 04/14/2005 | US20050079541 Immunoadhesin comprising a glycorprotein v1 domain |
| 04/14/2005 | US20050079538 polynucleotides which identify and encode human secreted proteins (SECP); expression vectors, host cells, antibodies, agonists, and antagonists; drug screening; anticarcinogenic agents |
| 04/14/2005 | US20050079537 Expression vector comprising nucleotide sequences coding membrane protein for in identifying modulator for prevention and treatment of cell proliferative, nervous system and inflammatory disorders |
| 04/14/2005 | US20050079530 Novel human kinase proteins and polynucleotides encoding the same |
| 04/14/2005 | US20050079503 Peptide comprising zinc binding of ubiquination protein for use as tool in identifying modulators for treatment and prevention of inflammation, reproductive and cell proliferation disorders |
| 04/14/2005 | US20050079496 Using nuclear factor of activated t-cells (nf-at) transcription factor expression as diagnostic tool detection and treatment of cell proliferative disorders |
| 04/14/2005 | US20050079495 Modified membrane protein comprising proteolytic and is absent for g-protein coupling for use as tool in diagnosis, prevention and treatment of pain, arthritis, asthma, psychological and gastrointestinal disorders |
| 04/14/2005 | US20050079235 Using green tea extract |
| 04/14/2005 | US20050079224 Residual solvent extraction method and microparticles produced thereby |
| 04/14/2005 | US20050079211 Use of lipid conjugates in the treatment of diseases of the nervous system |
| 04/14/2005 | US20050079183 Compounds having reduced immunogenicity and a method of reducing the immunogenicity of compounds |
| 04/14/2005 | US20050079177 Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases |
| 04/14/2005 | US20050079176 Treating stress response with chemokine receptor ccr5 modulators |
| 04/14/2005 | US20050079175 Administering receptor ligand protein suspension to prevent binding to lymphocytes |
| 04/14/2005 | US20050079173 Antibody that binds said inhibitor protein; interfering diagnostically or therapeutically with a wnt signal path; treatment of eye disorders, bone disorders, or tumors |
| 04/14/2005 | US20050079164 Solubilized CoQ-10 and carnitine |
| 04/14/2005 | US20050079163 Administering retroviral vector containing nucleic acid encoding a gene; antiproliferative agents; antitumor agents |
| 04/14/2005 | US20050079162 Method for improving oxygen transport by stored red blood cells |
| 04/14/2005 | US20050079158 Construct of anti-cancer recombinant adenovirus, method for preparing the same and use thereof |
| 04/14/2005 | US20050079156 Method of treating endometreosis |
| 04/14/2005 | US20050079154 Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
| 04/14/2005 | US20050079153 Methods for enhancing immune functions in neonatal mammals by administration of IL-18 |
| 04/14/2005 | US20050079151 Therapeutic agents for apoptosis-related diseases |
| 04/14/2005 | US20050079146 Mixture of ionic surfactant, chelate compound and solvent, preferable water; against grampositive, gramnegative bacteria |
| 04/14/2005 | DE10344848A1 New amidomethyl substituted 1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-n-acetic acid derivatives useful to treat cardiovascular disorders or diseases; hypertension; sexual dysfunction; or neurodegenerative disorders |
| 04/14/2005 | CA2776997A1 Method for the production of a cell and/or tissue and/or disease phase specific medicament |
| 04/14/2005 | CA2545639A1 Regulation of matrix metalloproteinases by psp94 family members |
| 04/14/2005 | CA2542002A1 Methods for modulating neuronal responses using inhibitors of ampa receptor endocytosis |
| 04/14/2005 | CA2541823A1 Hypoxia responsive human cngh 0002 genes and polypeptides |
| 04/14/2005 | CA2541240A1 Method for the production of a cell and/or tissue and/or disease phase specific medicament |
| 04/14/2005 | CA2541237A1 Modulation of activin to alter inflammatory responses |
| 04/14/2005 | CA2541018A1 Human prostate cancer cell factor(s) that induce stem cell commitment and osteogenesis |
| 04/14/2005 | CA2541006A1 Tim-3 polypeptides |
| 04/14/2005 | CA2540895A1 Combinations of ziconotide and opioids for reducing pain |
| 04/14/2005 | CA2540890A1 Treatment of demyelinating autoimmune disease with modified ordered peptides |
| 04/14/2005 | CA2540837A1 Mammalian t1r3 sweet taste receptors |
| 04/14/2005 | CA2540771A1 Nanoparticulate therapeutic biologically active agents |
| 04/14/2005 | CA2540742A1 Compositions and methods for treating burns |
| 04/14/2005 | CA2540703A1 Methods and compositions for mycoplasma pneumoniae exotoxins |
| 04/14/2005 | CA2540699A1 Polysaccharides for pulmonary delivery of active agents |
| 04/14/2005 | CA2540666A1 Glucocerebroside treatment of disease |
| 04/14/2005 | CA2540665A1 Human epo mimetic hinge core mimetibodies, compositions, methods and uses |
| 04/14/2005 | CA2540646A1 Antibacterial amide macrocycles |
| 04/14/2005 | CA2540520A1 Interacting polypeptide comprising a heptapeptide pattern and a cellular penetration domain |
| 04/14/2005 | CA2539440A1 Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions |
| 04/14/2005 | CA2539010A1 Gamma-tocopherol treatment for cystic fibrosis |
| 04/14/2005 | CA2537326A1 C1q related protein |
| 04/14/2005 | CA2535085A1 Tricalcium phosphates, their composites, implants incorporating them, and methods for their production |
| 04/14/2005 | CA2526425A1 Antigens targeted by prevalent pathogenic t cells in type 1 diabetes and uses thereof |
| 04/14/2005 | CA2524209A1 Antiviral agents for the treatment, control and prevention of infections by coronaviruses |
| 04/14/2005 | CA2515583A1 Hydrolases, nucleic acids encoding them and methods for making and using them |